

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

• **BLACK BORDERS**

- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

AMENDMENTS TO THE CLAIMS

This listing of the claims replaces all prior listings and versions:

1. (original): An isolated, non-canonical zinc finger binding protein comprising one or more non-canonical zinc finger components that bind to a target sequence.
2. (currently amended): The isolated ~~zinc finger binding protein~~ polynucleotide of claim 1 30, wherein the target sequence is a nucleic acid sequence.
3. (currently amended): The isolated ~~zinc finger binding protein~~ polynucleotide of claim 1 30, wherein the target sequence is an amino acid sequence.
4. (currently amended): The isolated ~~zinc finger binding protein~~ polynucleotide of claim 2, wherein the target sequence is DNA.
5. (currently amended): The isolated ~~zinc finger binding protein~~ polynucleotide of claim 2, wherein the target sequence is RNA.
6. (currently amended): The isolated ~~zinc finger binding protein~~ polynucleotide of claim 1 30, wherein the amino acid sequence of one or more of the zinc finger components is selected from the group consisting of: X₃-B-X₂₋₄-Cys-X₁₂-His-X₁₋₇-His-X₄; X₃-Cys-X₂₋₄-B-X₁₂-His-X₁₋₇-His-X₄; X₃-Cys-X₂₋₄-Cys-X₁₂-Z-X₁₋₇-His-X₄; X₃-Cys-X₂₋₄-Cys-X₁₂-His-X₁₋₇-Z-X₄; X₃-B-X₂₋₄-B-X₁₂-His-X₁₋₇-His-X₄; X₃-B-X₂₋₄-Cys-X₁₂-Z-X₁₋₇-His-X₄; X₃-B-X₂₋₄-Cys-X₁₂-His-X₁₋₇-Z-X₄; X₃-Cys-X₂₋₄-B-X₁₂-Z-X₁₋₇-His-X₄; X₃-Cys-X₂₋₄-B-X₁₂-Z-X₁₋₇-Z-X₄; X₃-Cys-X₂₋₄-Cys-X₁₂-Z-X₁₋₇-Z-X₄; X₃-Cys-X₂₋₄-B-X₁₂-Z-X₁₋₇-Z-X₄; X₃-B-X₂₋₄-Cys-X₁₂-Z-X₁₋₇-Z-X₄; X₃-B-X₂₋₄-B-X₁₂-His-X₁₋₇-Z-X₄; X₃-B-X₂₋₄-B-X₁₂-Z-X₁₋₇-His-X₄; and X₃-B-X₂₋₄-B-X₁₂-Z-X₁₋₇-Z-X₄, wherein X is any amino acid, B is any amino acid except cysteine and Z is any amino acid except histidine.
7. (currently amended): The isolated ~~zinc finger binding protein~~ polynucleotide of claim 6, wherein the zinc finger component comprises the sequence X₃-B-X₂₋₄-Cys-X₁₂-His-X₁₋₇-His-X₄, wherein X is any amino acid, B is any amino acid except cysteine and Z is any amino acid except histidine.

8. (currently amended): The isolated ~~zinc finger binding protein~~ polynucleotide of claim 6, wherein the zinc finger component comprises the sequence X₃-Cys-X₂₋₄-B-X₁₂-His-X₁₋₇-His-X₄, wherein X is any amino acid, B is any amino acid except cysteine and Z is any amino acid except histidine.

9. (currently amended): The isolated ~~zinc finger binding protein~~ polynucleotide of claim 6, wherein the zinc finger component comprises the sequence X₃-Cys-X₂₋₄-Cys-X₁₂-Z-X₁₋₇-His-X₄, wherein X is any amino acid, B is any amino acid except cysteine and Z is any amino acid except histidine.

10. (currently amended): The isolated ~~zinc finger binding protein~~ polynucleotide of claim 6, wherein the zinc finger component comprises the sequence X₃-Cys-X₂₋₄-Cys-X₁₂-His-X₁₋₇-Z-X₄, wherein X is any amino acid, B is any amino acid except cysteine and Z is any amino acid except histidine.

11. (currently amended): The isolated ~~zinc finger binding protein~~ polynucleotide of claim 6, wherein the zinc finger component comprises the sequence X₃-B-X₂₋₄-B-X₁₂-His-X₁₋₇-His-X₄, wherein X is any amino acid, B is any amino acid except cysteine and Z is any amino acid except histidine.

12. (currently amended): The isolated ~~zinc finger binding protein~~ polynucleotide of claim 6, wherein the zinc finger component comprises the sequence X₃-B-X₂₋₄-Cys-X₁₂-Z-X₁₋₇-His-X₄, wherein X is any amino acid, B is any amino acid except cysteine and Z is any amino acid except histidine.

13. (currently amended): The isolated ~~zinc finger binding protein~~ polynucleotide of claim 6, wherein the zinc finger component comprises the sequence X₃-B-X₂₋₄-Cys-X₁₂-His-X₁₋₇-Z-X₄, wherein X is any amino acid, B is any amino acid except cysteine and Z is any amino acid except histidine.

14. (currently amended): The isolated ~~zinc finger binding protein~~ polynucleotide of claim 6, wherein the zinc finger component comprises the sequence X₃-Cys-X₂₋₄-B-X₁₂-Z-X₁₋₇-His-X₄, wherein X is any amino acid, B is any amino acid except cysteine and Z is any amino acid except histidine.

15. (currently amended): The isolated ~~zinc finger binding protein~~ polynucleotide of claim 6, wherein the zinc finger component comprises the sequence X_3 -Cys- X_{2-4} -B- X_{12} -His- X_{1-7} -Z- X_4 , wherein X is any amino acid, B is any amino acid except cysteine and Z is any amino acid except histidine.

16. (currently amended): The isolated ~~zinc finger binding protein~~ polynucleotide of claim 6, wherein the zinc finger component comprises the sequence X_3 -Cys- X_{2-4} -Cys- X_{12} -Z- X_{1-7} -Z- X_4 , wherein X is any amino acid, B is any amino acid except cysteine and Z is any amino acid except histidine.

17. (currently amended): The isolated ~~zinc finger binding protein~~ polynucleotide of claim 6, wherein the zinc finger component comprises the sequence X_3 -Cys- X_{2-4} -B- X_{12} -Z- X_{1-7} -Z- X_4 , wherein X is any amino acid, B is any amino acid except cysteine and Z is any amino acid except histidine.

18. (currently amended): The isolated ~~zinc finger binding protein~~ polynucleotide of claim 6, wherein the zinc finger component comprises the sequence X_3 -B- X_{2-4} -Cys- X_{12} -Z- X_{1-7} -Z- X_4 , wherein X is any amino acid, B is any amino acid except cysteine and Z is any amino acid except histidine.

19. (currently amended): The isolated ~~zinc finger binding protein~~ polynucleotide of claim 6, wherein the zinc finger component comprises the sequence X_3 -B- X_{2-4} -B- X_{12} -His- X_{1-7} -Z- X_4 , wherein X is any amino acid, B is any amino acid except cysteine and Z is any amino acid except histidine.

20. (currently amended): The isolated ~~zinc finger binding protein~~ polynucleotide of claim 6, wherein the zinc finger component comprises the sequence X_3 -B- X_{2-4} -B- X_{12} -Z- X_{1-7} -His- X_4 , wherein X is any amino acid, B is any amino acid except cysteine and Z is any amino acid except histidine.

21. (currently amended): The isolated ~~zinc finger binding protein~~ polynucleotide of claim 6, the zinc finger component comprises the sequence X_3 -B- X_{2-4} -B- X_{12} -Z- X_{1-7} -Z-

X₄, wherein X is any amino acid, B is any amino acid except cysteine and Z is any amino acid except histidine.

22. (currently amended): The isolated ~~zinc finger binding protein~~ polynucleotide of claim + 30, wherein the target sequence is in a plant cell.

23. (currently amended): The isolated ~~zinc finger binding protein~~ polynucleotide of claim + 30, wherein the target sequence is in an animal cell.

24. (currently amended): The isolated ~~zinc finger binding protein~~ polynucleotide of claim 23, wherein the target sequence is in a human cell.

25. (currently amended): The isolated ~~zinc finger binding protein~~ polynucleotide of claim + 30, wherein the target sequence is a promoter sequence.

26. (currently amended): The isolated ~~zinc finger binding protein~~ polynucleotide of claim + 30, comprising three zinc finger components.

27. (currently amended): The isolated ~~zinc finger binding protein~~ polynucleotide of claim + 30, wherein the target sequence comprises about 9 to about 14 contiguous base pairs.

28. (currently amended): The isolated ~~zinc finger binding protein~~ polynucleotide of claim 26, wherein the third finger component comprises a non-canonical zinc finger component.

29. (cancelled)

30. (currently amended): An isolated polynucleotide encoding a non-naturally-occurring zinc-finger binding protein ~~according to claim +~~ comprising one or more non-C2H2 zinc finger components, wherein the protein is designed bind to a target sequence.

31. (original): An expression vector comprising the polynucleotide of claim 30.

32. (original): A host cell comprising the polynucleotide of claim 30.
33. (original): A fusion polypeptide comprising: (a) an isolated zinc finger binding protein according to claim 1 and (b) at least one functional domain.
34. (currently amended): The ~~fusion polypeptide~~ polynucleotide of claim 33 ~~claim 39~~, wherein the functional domain is a repressive domain.
35. (currently amended): The ~~fusion polypeptide~~ polynucleotide of claim 34, wherein the repressive domain is selected from the group consisting of KRAB, MBD-2B, v-ErbA, MBD3, TR and members of the DNMT family.
36. (currently amended): The ~~fusion polypeptide~~ polynucleotide of claim 35 ~~claim 39~~, wherein the functional domain is an activation domain.
37. (currently amended): The ~~fusion polypeptide~~ polynucleotide of claim 36, wherein the activation domain is selected from the group consisting of maize C1, VP16, p65 subunit of NF-kappa B, and VP64.
38. (currently amended): The ~~fusion polypeptide~~ polynucleotide of claim 37 ~~claim 39~~, wherein the functional domain is selected from the group consisting of an insulator domain, a chromatin-remodeling protein or a methyl-binding domain.
39. (currently amended): An isolated polynucleotide encoding ~~the a~~ a fusion polypeptide of claim 33 ~~, wherein the fusion polypeptide comprises: (a) a zinc finger binding protein according to claim 30 and (b) a functional domain.~~
40. (original): An expression vector comprising the polynucleotide of claim 39.
41. (original): A host cell comprising the polynucleotide of claim 39.
42. (currently amended): A method of modulating expression of a gene, the method comprising the step of contacting a region of DNA with a ~~fusion molecule~~ polynucleotide according to claim 33 ~~39~~.

43. (currently amended): The method of claim 42, wherein the zinc finger binding protein of the fusion molecule binds to a target site in a gene encoding a product selected from the group consisting of gamma-tocopherol methyl transferase (GMT), vascular endothelial growth factor, erythropoietin, androgen receptor, PPAR- γ 2, p16, p53, pRb, dystrophin and e-cadherin.

44. (original): The method of claim 42, wherein the functional domain comprises a repressive domain.

45. (original): The method of claim 44, wherein the repressive domain is selected from the group consisting of KRAB, MBD-2B, v-ErbA, MBD3, TR and members of the DNMT family.

46. (original): The method of claim 42, wherein the functional domain comprises an activation domain.

47. (currently amended): The method of claim 46, wherein the activation domain is selected from the group consisting of maize C1, VP16, p65 subunit of NF-kappa B, and VP64.

48. (original): The method of claim 42, wherein the functional domain is selected from the group consisting of an insulator domain, a chromatin-remodeling protein or a methyl-binding domain.

49. (original): The method of claim 42, wherein the gene is in a plant cell.

50. (original): The method of claim 42, wherein the gene is in an animal cell.

51. (original): The method of claim 50, wherein the gene is in a human cell.

52. (currently amended): A pharmaceutical composition comprising a ~~non-canonical zinc finger protein according to claim 1~~ non-naturally-occurring zinc-finger binding protein, wherein the zinc finger binding protein:

(a) comprises one or more non-C2H2 zinc finger components, and
(b) is designed bind to a target sequence; and
a pharmaceutically acceptable excipient.